Expanding the clinical and geographical spectrum of PARK-LRRK2 p.(Asn1437His): first report in a Swiss family
INTRODUCTION: Pathogenic variants in the LRRK2 gene represent the most common monogenic cause of Parkinson’s disease. Individual variants differ in frequency, geographical distribution and genotype-phenotype associations. Here, we report a Swiss family with multiple affected individuals carrying a very rare ROC-domain variant and provide a comprehensive characterisation of their clinical phenotype. CLINICAL FINDINGS: Age at onset was earlier than typically reported for PARK-LRRK2. Leg tremor was frequently the initial presenting symptom, followed by the development of an asymmetric akinetic-rigid syndrome with a clear dopaminergic response. Constipation was commonly reported, whereas significant cognitive symptoms were not evident. Notably, despite the high penetrance of the variant, disease progression was relatively mild. PRIMARY DIAGNOSIS: Genetic testing identified a heterozygous missense variant in the LRRK2 gene (c.4309A>C, p.(Asn1437His)), classified as likely pathogenic according to ACMG criteria. CONCLUSION: The present work expands both the geographical distribution of this rare ROC-domain variant and suggests that it may be associated with earlier onset but not necessarily greater disease severity. Continued characterisation of rare LRRK2 variants is essential for refining genotype-phenotype correlations and supporting emerging targeted therapies.
Authors
- Deborah Bartholdi
- Gerd Tinkhauser (ORCID: https://orcid.org/0000-0002-1954-1873)
- Paul Krack
- Georg Kägi
- Anina Bauer
- Jacob Clausen
- Christiane Zweier
- Mario Sousa
Institutions
- University of Bern (CH)
- University Hospital of Bern (CH)
Publication Details
- Journal
- Swiss Medical Weekly
- Published
- 2026-11-16
- DOI
- https://doi.org/10.57187/5519
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Boston Scientific Corporation
- Fondation Bertarelli
- Institut National de la Santé et de la Recherche Médicale
- Louis-Jeantet Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Association France Parkinson
- Fondation Roger de Spoelberch
- Merz Pharmaceuticals
- Parkinson Vereniging
- Idorsia Pharmaceuticals
- Parkinson Schweiz
- St. Jude Medical